Full Spectrum Hemp Oil

Full Spectrum Hemp Oil – Why It Matters

Full Spectrum Hemp OilFull spectrum hemp oil has a special extraction process where all of the cannabinoids, fatty acids, minerals, vitamins, proteins and terpenes found in the original hemp plant are present in the pure oil.

The reason full spectrum hemp oil matters is that treatment with full spectrum hemp oil has demonstrated far more health benefits than treatment with CBD alone.

This will be discussed further below, but the synergistic effect of treating the body with all these cannabinoids together is referred to as The Entourage Effect[1].

In order to understand how full spectrum oil affects your body, it is important to first cover the body’s Endocannabinoid System, or ECS.

Full Spectrum Hemp Oil And Your Endocannabinoid System (ECS)

Endocannabinoid System CB Receptors

If you missed that you had an Endocannabinoid System in high school biology, you should take comfort in the fact that it was first discovered by Dr. L.A. Matsuda in 1990[2].

In studying how THC intoxicates our bodies, scientists discovered that we have an entire endocannabinoid system (ECS) where neurotransmitters bind to cannabinoid receptors.

Our ECS system is not 100% understood yet, however, we do know that ECS is responsible for fine-tuning our balance with certain physiological functions, such as pain, sleep, memory, mood, appetite and inflammation.

As it turns out, there are two primary ECS receptors, CB1 and CB2, and these receptors react to different cannabinoids.

CB1 Receptors – These are primarily found in nerve cells in the brain and spinal cord, reproductive and urinary tracts, spleen, endocrine gland and white blood cells.

CB1 receptors are primarily responsible for the psychoactive effect you feel with THC.

CB2 Receptors –These are found in the immune system, white blood cells, spleen, brain, thymus gland, tonsils and gastrointestinal system.

CB2 receptors are responsible for cannabis’s medicinal properties, most notably its effect on treating inflammation. But there are far more benefits that we will cover further below.

Further adding to the importance of ECS, researchers and scientists have found that a shortage of cannabinoids in our system, referred to as endocannabinoid deficiency[53], can be a precursor to many diseases.

Now let’s discuss the primary cannabinoids found in full spectrum hemp oil, and how they can help.

The Cannabinoids In Full Spectrum Hemp Oil

There is a list of over 100 known cannabinoids, but here is a short list that has some very impressive qualities:

Full Spectrum CBDCBD – Cannabidiol is a non-psychoactive compound that has been the main topic of conversation in the media and at home.

CBD has demonstrated an exciting potential for treatment, and has shown notable results in treating the following disorders, conditions or diseases:

• Nausea[12]
• Vomiting
• Inflammation
• Pain[28,29]
• Arthritis[10]
• Migraines[3]
• Anxiety[8,9]
• Obesity
• Psychosis
• Schizophrenia
• Alzheimer’s[4,5,6,7]
• ALS (Amytotraphic Lateral Sclerosis)
• Parkinson’s[11]
• Multiple Sclerosis[13,14,15,16]
• Crohn’s Disease (IBS)[30,31]
• Epilepsy[23,24,25,26,27]
• Seizures[23,24,25,26,27]
• Cirrhosis
• Spinal Cord Injury
• Spinal Cord Disease
• Diabetes
• Cancer[17,18,19,20,21,22]

As you can see, there are numerous benefits to CBD. But don’t forget that thing called The Entourage Effect, which happens when you have all the cannabinoids found in full spectrum hemp oil – not just CBD alone.

Full Spectrum CBNCBN – Cannabinol has proven in studies to be a highly effective sleep aid, which makes it a therapeutic option for insomnia, sleep apnea and other sleeping disorders. Studies have shown that it significantly helps in prolonging sleep time.

Additionally, CBN has been found to treat the following disorders, conditions or diseases:

• Sleeping Aid[32,33,34]
• Inflammation[35]
• Pain[36]
• Bacteria
• Appetite Deficiency
• Glaucoma[37]
• Seizures
• Bone Growth[38,39,40,41]

One of the more notable study findings was that CBN achieved pain relief without interacting with our CB1 or CB2 receptors. This is exciting news since CBD works exclusively with the CB1 and CB2 receptors – which suggest that combining CBD and CBN could substantially increase pain relief.

Full Spectrum CBCCBC – Cannabichromene is a cannabinoid that has shown great promise in pain relief. Specifically, researchers found that CBC, when combined with CBD, increased pain relief compared to CBD alone.

However, CBC is not just about pain relief. As you might have guessed, CBC has also been found to treat the following disorders, conditions or diseases:

• Pain Relief[42]
• Depression[43,44]
• Fungus
• Bacteria
• Cancer Growth
• Inflammation
• Anxiety[45]
• Bone Density
• New Brain Cells

With regards to anxiety, one of the studies noted that CBC interacts with CB1 receptors to stimulate the release of chemicals that reduce excitability in the brain.

Similarly, CBD has an effect on the limbic and paralimbic areas of the brain to reduce anxiety. For those with anxiety issues, this suggests that combining CBC with CBD may prove to be most beneficial.

Full Spectrum CBDaCBDa – Cannabidiolic Acid is the acid precursor to CBD. It is found in abundant quantities in live plants. Through a process called decarboxylation, which can happen through process heat or sunlight, the CBDa turns into CBD.

Studies have shown that CBDa has been found to treat the following disorders, conditions or diseases:

• Nausea[46]
• Vomiting[46]
• Convulsing[46]
• Bacteria[47]
• Cancer
• Fungus[47]
• Inflammation
• Pain

CBDa has also demonstrated anti-oxidant properties, and was the subject of two promising studies which suggested that CBDa may have application for cancer in general, and aggressive breast cancer.

Full Spectrum CBGCBG – Cannabigerol is ironically, the chemical parent to CBD and THC. Enzymes break down most of this cannabinoid into THC and CBD. CBG has some very interesting properties as an anti-inflammatory, and shown to be particularly effective at treating glaucoma.

CBG has been found through studies to treat the following disorders, conditions or diseases:

• Glaucoma[48]
• Inflammatory Bowel Disease
• Huntington’s Disease[49]
• Cancer Cell Growth[50]
• Bacteria
• Appetite Deficiency

Researchers are now looking at ways of combining CBG with other cannabinoids to devise treatments for specific conditions.

Vitamins and Minerals in Full Spectrum Hemp Oil

Full Spectrum Vitamins And MineralsFull spectrum hemp oil has Vitamins A, B-complex, E, niacin, thiamine, riboflavin and beta-carotene (which is the precursor to Vitamin A).

Since beta-carotene is absent from so many diets, this is considered to be of significant health benefit.

As far as minerals, full spectrum hemp oil contains iron, potassium, magnesium, zinc, calcium and phosphorus.

These minerals play a role in the health of our blood, nerve, muscle, immune and skeletal systems.

Essential Fats and Proteins in Full Spectrum Hemp Oil

Full Spectrum Essential Fatty Acids
Full Spectrum Hemp Oil contains a significant amount of protein which is helpful in both building and repairing tissue.

Perhaps one of the most significant health ingredients in full spectrum hemp oil are all 20 amino acids, including the 9 essential ones.

“Essential” means that your body requires it, but does not produce it. Therefore, the only way to acquire these essential fatty acids is through diet.

Two of the most important essential fatty acids included in full spectrum hemp oil are Omega-3 and Omega-6.

The interesting thing to note here is that on average, our diet tends to balance these two essential acids in a 25:1 ratio – when they need to be in a 3:1 ratio. Full spectrum hemp oil contains these essential acids in the optimal 3:1 ratio.

Terpenes in Full Spectrum Hemp Oil

Full Spectrum TerpenesTerpenes are what give hemp and cannabis its flavor. There are 11 primary terpenes that drive the main aromas, plus approximately 20 other terpenes that are considered more minor in nature.

Let’s take a look at the 11 primary terpenes responsible for all of the flavor:

Caryophyllene – This is what gives black pepper its spiciness. Has been shown to fight anxiety, epilepsy and chronic pain. Works in tandem with the CB2 receptor.

Geraniol – Most commonly found in roses, bees also make it to mark flowers that are excellent sources of nectar. It is water insoluble and clear yellow in color.

Humulene – This terpene is the hoppy aroma you smell in beer because it picks it up from the hops when the beer is brewed.

Linalool – This terpene is found most often in lavender, and has been researched for its sedative and anti-anxiety properties. It has the smell of flowers with a dash of spice.

Limonene – Found in the rinds of all citrus fruits like oranges and lemons, this terpene has anti-depressant effects and improves absorption for skin and mucous membranes.

Myrcene – With a very clovey bouquet, this terpene appears to be closely associated with a sedative effect. It is found in many plants such as mango and hops.

Ocimene – Added to most perfumes, ocimene has sweet undertones. Research indicates that this terpene can help with inflammation and possibly as an anti-fungal.

Pinene – As expected, this terpene has a very piney scent, and is one of the most commonly found terpenes in nature. Known benefits include anti-inflammation, bronchodilator and increased alertness.

Terpineol – Contributing to a relaxing effect, terpineol is thought to be what confines you to a couch with certain strains. Research shows potential benefits as a sedative, as well as antibiotic and anti-inflammatory properties.

Terpinolene – Found in many fragrant plants like lilacs and apples, terpinolene has a very fresh citrus and pine aroma. Studies have shown potential for anti-fungal, anticancer and antioxidant properties.

Valencene – As the name suggests, this terpene is commonly found in Valencia oranges, and has the distinct aroma of oranges and grapefruit. Research shows evidence of anti-inflammatory properties, and is a known repellent of mosquitoes.

The Entourage Effect = Full Spectrum Hemp Oil

The Entourage EffectThe term The Entourage Effect was first coined in 1998 by two Israeli scientists, S. Ben-Shabat and Raphael Mechoulam, who were studying the effects of cannabis.

What they found was that when all cannabinoids were present, that it magnified the therapeutic benefits of the plant’s individual components.

In other words, there is far more medicinal benefit with the entirety of the whole plant compared to the sum of its parts.

Researchers were able to easily compare the effects of equal amounts of CBD isolate (CBD in pure form) versus that of full spectrum hemp oil, and found far greater medicinal value in the full spectrum.

In 2011, in another landmark study studying the synergistic nature of cannabinoids, Dr. Ethan Russo discovered the importance of terpenes[51] in therapy.

His findings indicated that terpenes have a high therapeutic value, however, they were typically lacking in CBD-only products.

Dr. Russo’s report also stated that cannabinoid-terpenoid interactions “could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections.”

With respect to cannabis oil which does have THC as well as all of the other cannabinoids, THC has been found to have multiple and significant therapeutic roles as well.

One example is that THC inhibits an enzyme implicated in the formation of beta amyloid plaque, the hallmark of Alzheimer’s-related dementia[52].

Another interesting fact is that CBD and certain terpenes can act as a ‘governor’ with respect to THC, often times significantly diminishing the effects of THC.

Full spectrum hemp oil does not, by legal definition, contain more than 0.3% THC, which means it has no psychoactive effects.

Is Full Spectrum Hemp Oil Legal?

Is Full Spectrum Hemp Oil Legal?The short answer is that full spectrum hemp oil is legal in all 50 states. That said, we will make an important distinction here, and so should you.

Hemp and Marijuana both come from the same plant family, cannabis. And companies are able to make full spectrum hemp oil from both plants. However, full spectrum hemp oil is only legal if it is derived from hemp plants.

If it sounds confusing, it is – because the laws have not yet caught up to the science.

Companies can extract out the THC from marijuana plants, thus providing the exact same ingredients as full spectrum hemp oil. But the law says if it is derived from marijuana plants (and not from hemp plants), the full spectrum oil would then be considered illegal in 40 states.

Although companies are smart enough to avoid selling illegal products on a state-by-state basis, the most important task for consumers (in 40 of our 50 states) is to double-check that the pure spectrum hemp oil was made from hemp plants.

1. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998, July) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol, 17;353(1):23-31.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990, September) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284):561-4.
3. Baron, E.P. (2015, June). Comprehensive Review of Medicinal Cannabis, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. Headache, 55(6), 885-916.
4. Campbell, V.A., and Gowran, A. (2007, November). Alzheimer’s disease, taking the edge off with cannabinoids? British Journal of Phamacology, 152(5), 655-662.
5. Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., and de Ceballos, M.L. (2011, June). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Molecular Pharmacology, 79(6), 964-73.
6. Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., and de Ceballos, M.L. (2005, February). Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience, 25(8), 1904-13.
7. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A.A. (2004, April). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. Journal of Neurochemistry, 89(1), 134-41.
8. Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simoes, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M.C., McGuire, P.K., Zuardi, A.W., Busatto, G.F., and Hallak, J.E. (2011, January). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121-30.
9. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A.E., Martin-Santos, R., Hallak, J.E., Zuardo, A.W., and Crippa, J.A. (2011, May). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219-26.
10. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., and Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America, 97(17), 9561–9566.
11. Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., dos Santos, A.C., Teixeira, A.L., Hallak, J.E., and Crippa, J.A. (2014, November). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of Psychopharmacology, 29(11), 1088-98.
12. Parker, L.A., Rock, E.M., and Limbeer, C.L. (2011, August). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163(7), 1411-22.
13. Barnes, M.P. (2006, April). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy, 7(5), 607-15.
14. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. (2010, June). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research, 32(5), 451-9.
15. Kozela, E., Lev., N., Kauschansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., and Vogel, Z. (2011, August). Cannabidiol inhibits pathogentic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL-6 mice. British Journal of Pharmacology, 163(7), 1507-19.
16. Mecha, M., Feliu, A., Inigo, P.M., Mestre, L., Carrillo-Salinas, F.J., and Guaza, C. (2013, November). Cannabidiol provides long-lasting protection against the deletrious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiology of Disease, 59, 141-50.
17. Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006, September). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharacologogy and Experimental Therapeutics, 318(3), 1375-87.
18. McAllister, S.D., Christian, R.T., Horowitz, M.P., Garcia, A., and Desprez, P.Y. (2007, November). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics, 6(11), 2921-7.
19. McAllister, S.D., Murase, R., Christian, R.T., Lau, D., Zielinski, A.J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., Liu, Y, Debs, R.J., Moore, D.H., and Desprez, P.Y. (2011, August). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment, 129(1), 37-47.
20. McAllister, S.D., Soroceanu, L., and Desprez, P.Y. (2015, June). The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of Neuroimmune Pharmacology, 10(2), 255-67.
21. Orellana-Serradell, O., Poblete, C.E., Sanchez, C., Castellon, E.A., Gallegos, I., Huidobro, C., Llanos, M.N., and Contreras, H.R. (2015, April). Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncology Reports, 33(4), 1599-608.
22. Takeda, S., Okazaki, H., Ikeda, E., Abe, S., Yoshioka, Y, Watanabe, K., and Aramaki, H. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. The Journal of Toxicological Sciences, 39(5), 711-6.
23. Blair, R.E., Deshpande, L.S., and DeLorenzo, R.J. (2015, September). Cannabinoids: is there a potential treatment role in epilepsy? Expert Opinion on Pharmacology, 16(13), 1911-4.
24. Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Asward, D., Notcutt, W.G., Martinez-Orgado, J., Robson, P.J., Rohrback, B.G., Thiele, E., Whalley, B., and Friedman, D. (2014, June). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802.
25. Rosenberg, E.C., Tsien, R.W., Whalley, B.J., and Devinsky, O. (2015, October). Cannabinoids and Epilepsy. Neurotherapeutics, (4):747-68.
26. Szaflarski, J.P., and Bebin, E.M. (2014, December). Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy & Behavior, 41, 277-82.
27. Hussain, S.A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Hung, P., Lerner, J.T., and Sankar, R. (2015, June). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy & Behavior, 47, 138-41.
28. Baron, E.P. (2015, June). Comprehensive Review of Medicinal Cannabis, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. Headache, 55(6), 885-916.
29. Jensen, B., Chen, J., Furnish, T., and Wallace, M. (2015, October). Cannabinoids and Chronic Pain: a Review of Basic Science and Clinical Evidence. Current Pain and Headache Reports, 19(10), 524.
30. Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., and Konikoff, F.M. (2013, October). Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology, 11(10), 1276-1280.
31. Ravikoff Allegretti, J., Courtwright, A., Lucci, M., Korzenik, J.R., and Levine, J. (2013, December). Cannabis use patterns among patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 19(13), 2809-14.
32. Takahaski, R.N., Karniol, I.G. (1975). Pharmacologic interaction between cannabinol and delta9-tetrahydrocannabinol. Psychopharmacologia, 41(3), 277-84.
33. Usami, N., Kobana, K., Yoshida, H., Kimura, T., Watanabe, K., Yoshimura, H., and Yamamoto, I. (1998, September). Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. Chemical & Pharmaceutical Bulletin, 46(9), 1462-7.
34. Yoshida, H., Usami, N., Ohishi, Y, Watanabe, K., Yamamoto, I., and Yoshimura, H. (1995, February). Synthesis and pharmacological effects in mice of halogenated cannabinol derivatives. Chemical & Pharmaceutical Bulletin, 43(2), 335-7.
35. Croxford, J.L., and Yamamura, T. (2005, September). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Journal of Neuroimmunology, 166(1-2), 3-18.
36. Zygmunt, P.M., Andersson, D.A., and Hogestatt, E.D. (2002, June 1). 9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism. The Journal of Neuroscience, 22(11), 4720-4727.
37. Colasanti, B.K., Craig, C.R., and Allara, R.D. (1984, September). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Experimental Eye Research, 39(3), 251-9.
38. Idris, A.I., van’t Hof, R.J., Greig, I.R., Ridge, S.A., Baker, D., Ross, R.A., and Ralston, S.H. (2005, July). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nature Medicine, 11(7), 774-9.
39. Idris, A.I., Sophocleous, A., Landao-Bassonga, E., van’t Hof, R.J., and Ralston, S.H. (2008, November). Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology, 149(11), 5619-26.
40. Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., Mechoulam, R., Zimmer, A., and Bab, I. (2006, January 17). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proceedings of the National Academy of Sciences of the United States of America, 103(3), 696-701.
41. Scutt, A., and Willilamson, E.M. (2007). Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcified Tissue International, 80, 50-59.
42. Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., and Di Marzo, V. (2011, February). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. British Journal of Pharmacology, 162(3), 584-96.
43. El-Alfy, A.T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., Khan, I., ElSohly, M., and Ross, S. (2010, June). Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology, Biochemistry, and Behavior, 95(4), 434-42.
44. Shinjyo, N., and Di Marzo, V. (2013, November). The effect of cannabichromene on adult neural stem/progenitor cells. Neurochemistry International, 63(5), 432-437.
45. Ramikie, T.S., Nyilas, R., Bluett, R.J., Gamble-George, J.C., Hartley, N.D., Mackie, K., Watanabe, M., Katona, I., and Patel, S. (2014, March 5). Multiple mechanistically distinct modes of endocannabinoid mobilation of central amygdala glutamatergic synapses. Neuron, 81(5), 1111-25.
46. D Bolognini, EM Rock, NL Cluny, MG Cascio, CL Limebeer, M Duncan, CG Stott, FA Javid, LA Parker, RG Pertwee1 (2013, March) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. British Journal of Pharmacology, 168(6): 1456–1470.
47. Turner, C.D., and Elsohly, M.A. (1981, August-September). Biological activity of cannabichromene, its homologs and isomers. Journal of Clinical Pharmacology, 21 (8-9 Suppl), 238S-291S.
48. Nadolska K1, Goś R. (2008) Possibilities of applying cannabinoids’ in the treatment of glaucoma. Klin Oczna, 110(7-9):314-7.
49. Valdeolivas S1, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. (2015, January) Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1):185-99.
50. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. (2014, December) Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35(12):2787-97.
51. Ethan B Russo (2011 August) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7): 1344–1364.
52. Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., and Cai, J. (2014). The potential therapeutic effects of THC on Alzheimer’s disease. Journal of Alzheimer’s Disease, 42(3), 973-84.
53. Russo EB (2004, April) Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Letters, 25(1-2):31-9.
Spread the love